It's that time of the year again for you to prepare for the NPPO Annual Report to Congress. Are you ready? Here's the original message from NPPO and also their attached worksheet. Good Luck!

---

We will be holding several training sessions highlighting errors to avoid in the Annual Report.  We found the NPCs with the most errors last year did not attend the training, so please plan to attend one of the sessions.  We will hold them over two weeks, one am, one mid-day and one late afternoon.  June 1^st is on a Saturday this year, so the deadline will be extended until June 3, 2019.  Early submissions are greatly appreciated.

Attached please find the 2018 NPC Annual Report Template.  Please submit this form and the other required documents by email to vhaconppo@va.gov  by June 3, 2019.  Our timeline to submit this is mid-August, so we really need your report by June 3, 2019.  Your cooperation in carefully reading the following submission instructions will be greatly appreciated:

1. The subject line of the submission email should be titled: “Name of your city, state – NPC Annual Report for 2018.”

1. The documents attached to the email should be:

1. NPC Annual Report Form – please title the document as “Name of your city, state – NPC Annual Report for 2018”
2. Form 990 – please title the document as “Name of your city, state – Form 990 for 2018”
3. Audited financial statements – please title the document as “Name of your city, state – Audited Financials for 2018”
4. Audit Management Letter (letter from auditors, if any) – please title the document as “Name of your city, state – Audit Management Letter (from Auditors) for 2018”

     Please do not send us copies of any letters that you have written to your auditors. 

     We only want copies of letters that your auditors have written to you.  Also, please

     submit files that are not password protected.

Please keep in mind that your NPC must have an audit done by an independent outside auditor if your annual revenues are $500,000 or more.  If your NPC’s revenues are between $100,000 and $500,000 for the year, then an audit by an independent outside auditor is required only every three years.  Those NPCs with revenues less than $100,000 a year do not need to have audits by independent outside auditors.

Common errors to be avoided are:

1. Not labeling your documents as specified above.
2. Total revenues and total expenses amounts shown on Tab 4 do not agree exactly with the amounts for revenues and expenses shown on page 1 of the Form 990.
3. The net assets amount shown on Tab 6 does not agree with the net assets amount shown on page 1 of the Form 990.
4. The amount of government funding received on Tab 4 should equal or exceed the total of the amount entered on Tab 7 for governmental funding sources greater than $25,000.
5. The amount of non-governmental funding received should equal or exceed the total of the amount entered on Tab 8 for non-governmental funding sources greater than $25,000.
6. Identifying non-governmental funding sources as being from universities when in fact they are from Federal sources.  Please identify the Federal sources and show the amounts on Tab 7 for governmental funding sources greater than $25,000.
7. Not listing payments to employees greater than $50,000 on Tab 9.  Please de-identify the employees listed using an employee number or other number.
8. Not listing at least three accomplishments for your NPC on Tab 10.  Please keep your “accomplishments” succinct, 20 words or less.
9. Not showing any payroll taxes paid on Tab 5, Line 10.

• 10.   Not listing Management and General expenses on Tab 5, Column (C).
• 11.   Not filing the Single Audit Reports along with the audited financial statements if a Uniform Guidance audit is required.
• 12.   Filing letters you have written to your auditors.  We are only interested in having copies of letters from your auditors back to you regarding audit findings, recommendations, deficiencies, and material weaknesses, if any.
• 13.   Breaking up a report into more than one file.  We must have one file for each report.
• 14.   Submitting password protected files.  We must be able to open, read, and, if convenient for us, be able to print the documents you are submitting.

                                                                           

If you have any questions about how to properly complete the 2018 NPC Annual Report, please contact Allan Krehbiel at 301-569-3847 or allan.krehbiel@va.gov.

Thank you in advance for submitting your 2018 NPC Annual Report by June 3.  Your cooperation in making a timely filing will be greatly appreciated and is necessary to meet the deadlines set by the Secretary and the U.S. Congress.

2018 NPC Annual Report Template - Rev. 1-02-18.xls

The FY19 Defense Appropriation provides $7.5 million (M) to the Department of Defense Autism Research Program (ARP)to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The ARP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 ARP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19arppreann

Clinical Trial Award

• Investigators at or above the level of Associate Professor (or equivalent), or
• Nested Early-Career Investigator Option: Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria at the application submission deadline date:
• Must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline
• Is no more than 7 years from the receipt of a terminal degree
• Has the freedom to commit at least 50% time to the project
• Supports research with the potential to have a major impact on the treatment and/or management of ASD.
• Preliminary data relevant to the proposed clinical trial are required.
• Pre-application is required; application submission is by invitation only.
• Nested Early-Career Investigator Option: Supports the development of young investigators pursuing or wishing to pursue a career in ASD clinical trial research.
• Maximum funding of $1,000,000 for direct costs (plus indirect costs)
• Maximum period of performance is 4 years
• Nested Early-Career Investigator Option:
• Maximum funding of $1,155,000 for direct costs (plus indirect costs)
• Maximum period of performance is 4 years

Clinical Translational Research Award

• Investigators at or above the level of Assistant Professor (or equivalent)
• Supports early-phase, proof-of-principle clinical trials with the potential to have a major impact on the treatment and/or management of ASD.
• Preliminary data relevant to the proposed project are required.
• Pre-application is required; application submission is by invitation only.
• Maximum funding of $500,000 for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

Idea Development Award

• Investigators at or above the level of Assistant Professor (or equivalent), or
• Multiple PI Option: 
  Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator and receive a separate award. 
• Supports the development of innovative, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.  Preliminary data relevant to the proposed project are required.
• Pre-application is required; application submission is by invitation only.
• Clinical trials or applications including a clinical trial aim are not allowed.
• Maximum funding of $500,000 for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in February 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Focus Areas:  The goal of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (TSC), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY19 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY19 Focus Areas:

• Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
• Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
• Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions
• Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization

https://cdmrp.army.mil/pubs/press/2019/19tscrppreann

Exploration – Hypothesis Development Award

• Investigators at or above postdoctoral fellow (or equivalent)
• Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.
• Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
• Preliminary data are not required.
• Research projects must be innovative, feasible, and supported by a strong rationale.
• Innovation is an important review criterion.
• Clinical trials are not allowed.
• Maximum funding of
• $150,000 for direct costs (plus indirect costs)
• Maximum period of performance is 2 year

Idea Development Award

Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);

OrNew Investigators:  

• Independent investigator at or below the level of Assistant Professor (or equivalent); or
• Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC, thereby bringing his/her expertise to the field.
• Must not have received more than $300,000 in total direct costs for previous or concurrent TSC research as a Principal Investigator of one or more Federally funded, non-mentored peer-reviewed grants. (National Institutes of Health K/R00 Awardees are eligible to apply.)
• Must not have received a New Investigator Award previously from any program within the CDMRP.
• Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.
• Preliminary data are expected.
• Impact and Innovation are important review criteria.
• Clinical trials are not allowed.
• New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in TSC research.
• Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately
• Maximum funding of $450,000 for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

Clinical Translational Research Award

• Independent investigators at or above the level of Assistant Professor (or equivalent)
• Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.
• Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.
• Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 
• Preclinical studies may be appropriate but must include a clinical component.
• Projects that are exploratory and/or strictly animal research will not be considered for funding.
• Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
• Clinical Translational Potential is an important review criterion.
• Preliminary data are required.
• Maximum funding of $600,000 for direct costs (plus indirect costs)
• Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $130 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:

• ·         Prevent breast cancer (primary prevention)
• ·         Identify determinants of breast cancer initiation, risk, or susceptibility
• ·         Distinguish deadly from non-deadly breast cancers
• ·         Conquer the problems of overdiagnosis and overtreatment
• ·         Identify what drives breast cancer growth; determine how to stop it
• ·         Identify why some breast cancers become metastatic
• ·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• ·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• ·         Eliminate the mortality associated with metastatic breast cancer

https://cdmrp.army.mil/funding/bcrp

The FY19 Defense Appropriation provides $8 million (M) to the Department of Defense Military Burn Research Program (MBRP)to support a broad research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The overarching goal for the FY19 MBRP is to support the development or refinement of interventions or technologies that will enable non-medical or medical first responders to provide appropriate burn care closer to the point of injury to enhance the potential for better long-term outcomes. The MBRP anticipates that outcomes of successful applications will lead to near-term interventions, products, or care guidelines that will assist fellow Service members, first responders, and/or civilians in the pre-hospital care of the severe burn casualty.

The FY19 MBRP will solicit research applications towards this goal that specifically address burn wound conversion prevention, non-surgical burn wound debridement strategies, and/or temporary coverage products.

The MBRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 MBRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in or before March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19mbrppreann

Idea Development Award

• Independent investigators at all academic levels (or equivalent) may be named as PI in the application.
• Supports innovative research in the field of burn wound care
• Inclusion of preliminary and/or published data relevant to the proposed research is required.
• Feasibility and Impact are important review criteria.
• Clinical trials are not allowed.
• Maximum funding of $500,000 for total costs (direct costs plus indirect costs)
• Maximum period of performance is 3 years Pre-application is required; application submission is by invitation only.

Clinical Translational Research Award

• Independent investigators at all academic levels (or equivalent) may be named as PI in the application
• Supports clinical research projects that are likely to have a major impact on therapy by applying promising and well-founded laboratory, pre-clinical, or clinical research findings to the care of the burn-injured patient.
• The proposed study must include clinical research, and may include initial proof of concept trials, studies involving use of human anatomical substances, observational studies, and/or involve some retrospective data analysis.
• Preliminary data is required.
• Animal research is not allowed.
• Pre-application is required; application submission is by invitation only.
• Maximum funding of $1.55 million (M) for total costs (direct costs plus indirect costs)
• Maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The NIH has a funding opportunity available that might be beneficial for your NPC! There are now open RFAs related to the HEAL (Helping to End Addiction Long-termSM) ) initiative. Learn more about the initiative and opportunities with the link below:

https://www.aamc.org/download/493374/data/nihheal.pdf

The FY19 Defense Appropriation provides $130 million (M) to the Department of Defense Breast Cancer Research Program (BCRP) to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The BCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in January 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

Applications submitted to the FY19 BCRP must address one or more of the following overarching challenges:

• Prevent breast cancer (primary prevention)
• Identify determinants of breast cancer initiation, risk, or susceptibility
• Distinguish deadly from non-deadly breast cancers
• Conquer the problems of overdiagnosis and overtreatment
• Identify what drives breast cancer growth; determine how to stop it
• Identify why some breast cancers become metastatic
• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• Eliminate the mortality associated with metastatic breast cancer

https://cdmrp.army.mil/pubs/press/2019/19bcrppreann

Breakthrough Award

• Investigators at all academic levels (or equivalent)
• Senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship
• Award are encouraged to apply under Funding Levels 1 and 2
• Supports promising research that has high potential to lead to or make breakthroughs in breast cancer.
• Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.
• Partnering PI Option allows two Principal Investigators (PIs), termed Initiating and Partnering PIs, to collaborate on a single application.
• Different funding levels, based on the scope of research, are available.  It is the responsibility of the PI to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

• Funding Level 1:  Innovative, high-risk/high-reward research that is in the earliest stages of idea development.  In order to foster research with clearly defined potential to yield new avenues of investigation, preliminary data are not required. Proof-of-concept is the anticipated outcome.
• Funding Level 2:  Preclinical research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
• Funding Level 2 – Population Science and Prevention Studies: With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.
• Funding Level 3:  Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require US Food and Drug Administration (FDA) involvement, applications must demonstrate availability of and access to clinical reagents (e.g. therapeutic molecules) and subject population(s). Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g. first in human; Phase I/Ib) may be appropriate.
• Funding Level 4:  Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer.  Human clinical trials are required. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical project successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents. For proposed research that will require FDA involvement, project readiness requirements at the time of application submission include: proof of availability of and access to clinical reagents (e.g. therapeutics) that meet regulatory compliance guidelines; proof of availability of and access to appropriate subject population(s); validated projections for patient recruitment; and submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the FDA, if applicable.

Funding Levels 1 and 2:

·       Submission of a Letter of Intent is required prior to full application submission.

·       Each PI may submit only one application as a PI or Initiating PI for each funding level.  There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·       Additional funds are available for applications submitted under the Partnering PI Option.

·       Clinical trials are not allowed.

Funding Levels 3 and 4:

·       Submission of a preproposal is required; application submission is by invitation only.

·       Each PI may submit only one application as a PI or Initiating PI for each funding level.  There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly unique, meaningful collaborations addressing distinct research questions.

·       Additional funds are available for Funding Level 3 applications submitted under the Partnering PI Option.

·       PIs must include two or more breast cancer advocates on their research team.

Clinical trials are allowed (Funding Level 3) or required (Funding Level 4).

Funding Level 1:

Maximum funding of $450,000 for direct costs (plus indirect costs)

Maximum period of performance is 3 years

Funding Level 1 – Partnering PI Option:

Maximum funding of $750,000 for direct costs (plus indirect costs)

Maximum period of performance is 3 years

Funding Level 2:

Maximum funding of $1 million (M) for direct costs (plus indirect costs)

Maximum period of performance is 3 years

Funding Level 2 – Partnering PI Option:

Maximum funding of $1.5M for direct costs (plus indirect costs)

Maximum period of performance is 3 years

Funding Level 2 – Population Science and Prevention Studies

Maximum funding of $1.5M for direct costs (plus indirect costs)

Maximum period of performance is 4 years

Funding Level 2 – Population Science and Prevention Studies – Partnering PI Option

Maximum funding of $2M for direct costs (plus indirect costs)

Maximum period of performance is 4 years

Funding Level 3:

Maximum funding of $3M in direct costs (plus indirect costs)

Maximum period of performance is 4 years

Funding Level 3 – Partnering PI Option:

Maximum funding of $4M for direct costs (plus indirect costs)

Maximum period of performance is 4 years

Funding Level 4 and Funding Level 4 – Partnering PI Option:

Maximum funding of $10M for direct costs (plus indirect costs)

Maximum period of performance is 4 years

Breakthrough Fellowship Award

As of the application submission deadline, all eligible PIs must have:

·       Successfully completed the requirements for a doctoral or medical degree, and

·       Been in the laboratory or clinical research setting in which the proposed research is to be performed for no more than 2 years, and

·       A total of less than 4 years’ experience in a postdoctoral fellowship or mentored clinical research training program (excludes any clinical residency or fellowship training)

Mentor

·       Must have breast cancer research experience, including current funding and recent publications

·       Supports exceptionally talented, “best and brightest” recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research.

·       Proposed research must have high potential to lead to or make breakthroughs in breast cancer and show evidence of rigorous experimental design, sufficient experimental details, appropriate controls, pitfalls and alternatives, and a statistical plan.

·       Individualized researcher development plan and mentorship should prepare the PI for an independent career at the forefront of breast cancer research or patient care.

·       The PI is not required to have previous experience in breast cancer research.

·       Submission of a Letter of Intent is required prior to full application submission.

·       Maximum funding of $300,000 for direct costs (plus indirect costs)

·       Maximum period of performance is 3 years

Era of Hope Scholar Award

• Independent, non-mentored investigators within 6 years of their last training position (e.g., postdoctoral fellowship, medical residency, clinical fellowship) as of the application submission deadline

·       Supports exceptionally talented, early-career scientists who have demonstrated that they are the “best and brightest” in their fields through extraordinary creativity, vision, innovation, and productivity.

·       PIs should articulate a vision that challenges current dogma and demonstrates an ability to look beyond tradition and convention.

·       PIs must demonstrate experience in forming effective partnerships and collaborations and exhibit strong potential for future leadership in breast cancer.

·       PIs are required to include two or more breast cancer advocates on their research team.

• Submission of a Letter of Intent is required prior to full application submission.

·       Maximum funding of $3M for direct costs (plus indirect costs)

• Maximum period of performance is 4 years

Innovator Award

• Associate Professor or above (or equivalent).

·       Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field.

·       Provides opportunity to pursue novel, visionary, high-risk ideas that will accelerate progress toward ending breast cancer.

·       PIs must include two or more breast cancer advocates on their research team.

Submission of a preproposal is required; application submission is by invitation only.

·       Maximum funding of $5M for direct costs (plus indirect costs).

• Maximum period of performance is 4 years

Distinguished Investigator Award

• Assistant Professor or above (or equivalent) and more than 6 years beyond the PI’s last training position as of the application submission deadline

·       Seeks new paradigms in breast cancer research by supporting investigators who are established and recognized leaders with a renowned reputation as a researcher who has made groundbreaking contributions to advancing their field and who propose a fundamental shift from their track record of research.

·       Does not support continuation of or incremental changes from the PI’s published line of research. A shift from a different malignancy to breast cancer may not constitute a fundamental shift.

·       If the PI is not an established breast cancer researcher, he/she must clearly articulate a motivation and commitment for proposing a conceptual shift in his/her research and must include at least one collaborator with breast cancer expertise.

·       PIs must include two or more breast cancer advocates on their research team.

·       High-risk/high-reward projects pursuing innovative new paradigms are encouraged, but not required.

·       Submission of a preproposal is required; application submission is by invitation only.

·       Maximum funding of $3M for direct costs (plus indirect costs)

·       Maximum period of performance is 4 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Ovarian Cancer Research Program (OCRP) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

The OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in January 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

https://cdmrp.army.mil/pubs/press/2019/19ocrppreann

Clinical Development Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

·        Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.

·        Near-term impact is expected.

·        Preclinical studies in animals are not allowed.

·        Small-scale clinical trials (Phase 0, Phase 1, Pilot) studies enriching a clinical trial and projects related to or associated with ongoing or completed clinical trials are allowed.

·        Preliminary data are required.

·        Optional Nested Early-Career Investigator (ECI):  Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.

·        Pre-application is required; application is by invitation only.

·        Maximum funding of $600,000 for direct costs (plus indirect costs).

·        With the ECI option, the maximum funding is $800,000 for direct costs (plus indirect costs).

·        Maximum period of performance is 3 years.

Investigator-Initiated Research Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

·        Supports meritorious basic and clinically oriented research in ovarian cancer.

·        Impact is an important review criterion.

·        Preliminary data are required.

·        Clinical trials are not allowed. 

·        Pre-application is required; application is by invitation only.

·      Maximum funding of $450,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 3 years.

Ovarian Cancer Academy Award – Early-Career Investigator

Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline.  A letter attesting to eligibility is required.

·      Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.

·      ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.

·      A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.

·      A Designated Mentor may only mentor one ECI candidate.

·      The Designated Mentor is not required to be at the same institution as the ECI.

·      Preliminary data are required.

·      Clinical trials are allowed.

·      Maximum funding of $725,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 4 years, with a 5^th-year option.

·      Pre-application is required; application is by invitation only.

Ovarian Cancer Academy Dean Award

Dean must be an established ovarian cancer researcher.

·      Embedded Assistant Dean must be an independent ovarian cancer research at a different institution from the Dean.

·      Supports visionary individuals who are established ovarian cancer researchers with a strong record of mentoring and commitment to leadership.

·      Academy Dean, with Assistant Dean, will oversee an interactive academy of ECIs and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the ECIs.

·      Pre-application is required; application is by invitation only.

·      Maximum funding of $1,750,000 in direct costs (plus indirect costs).

·      The Dean and Assistant Dean are expected to be partners in leading the Academy, and the direct cost funding should be divided accordingly.

·      Period of performance is 4 years, with a 5^th-year option.

Pilot Award

Investigators at or above the postdoctoral level (or equivalent).

·      Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.

·      Innovation and Impact are important review criteria.

·      Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.

·      Clinical trials are not allowed.

·      Pre-application is required and blinded; application submission is by invitation only.

·      Maximum funding of $250,000 for direct costs (plus indirect costs).

·      Maximum period of performance is 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org.  For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

The FY19 Defense Appropriations Act provides $10 million (M) to the Department of Defense Amyotrophic Lateral Sclerosis Research Program (ALSRP)to support innovative and high-impact research into preclinical development of therapeutics for Amyotrophic Lateral Sclerosis.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation.  The managing agent for the Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The mission of the ALSRP is to fund innovative preclinical research to develop new treatments for ALS for the benefit of Service members, Veterans, and the general public.

https://cdmrp.army.mil/funding/alsrp

The following mechanisms have been released:

Therapeutic Development Award – Preproposal due by 3/22/19

• Independent investigators at all academic levels
• Pre-application is required; full application submission is by invitation only
• Supports post-discovery, preclinical development of therapeutics for ALS
• Preliminary data, including identity and purity of an identified bioactive compound(s), are required
• Therapeutically Relevant Marker Option available
• Collaboration with industry is encouraged
• Clinical trials are not allowed

• Maximum funding of $1.0 million for direct costs (plus indirect costs); $1.25 million for direct costs (plus indirect costs) for applications including the Therapeutic Relevant Marker Option
• Maximum period of performance is 2 years

Therapeutic Idea Award – Preproposal due by 3/22/19

• Independent investigators at all academic levels
• Pre-application is required; full application submission is by invitation only
• Supports screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development
• Preliminary data are not required
• Not intended to support projects focusing on the pathophysiology of ALS
• Maximum funding of $500,000 for direct costs (plus indirect costs)
• Maximum period of performance is 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the ALSRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@Ebrap.org

Book mark the CDMRP website:

cdmrp.army.mil

Follow CDMRP on Twitter at:

twitter.com/CDMRP

View CDMRP research results on YouTube:

www.youtube.com/user/CDMRP

Like us on FaceBook:

www.facebook.com/TheCDMRP

The FY19 Defense Appropriations Act provides $350 million (M) to the Department of Defense Peer Reviewed Medical Research Program (PRMRP) to support or medical research projects of clear scientific merit and direct relevance to military health.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

The PRMRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRMRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in November 2018.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

The vision and mission of the PRMRP is improve the health, care, and well-being of all military Service members, Veterans, and beneficiaries by encouraging, identifying, selecting, and managing medical research projects of clear scientific merit and direct relevance to military health.
Congressionally Directed Topic Areas:  All applications submitted to the PRMRP must address at least one of the FY19 PRMRP Congressionally directed topic areas.  The FY19 PRMRP Topic Areas are as follows:
 
.       Acute Lung Injury
.       Antimicrobial Resistance
.       Arthritis
.       Burn Pit Exposure
.       Cardiomyopathy
.       Cerebellar Ataxia
.       Chronic Migraine and Post-Traumatic Headache
.       Congenital Heart Disease
.       Constrictive Bronchiolitis
.       Diabetes
.       Dystonia
.       Eating Disorders
.       Emerging Infectious Diseases
.       Epidermolysis Bullosa
.       Focal Segmental Glomerulosclerosis
.       Frontotemporal Degeneration
.       Guillain-Barré Syndrome
.       Hemorrhage Control
.       Hepatitis B
.       Hereditary Angioedema
.       Hydrocephalus
.       Immunomonitoring of Intestinal Transplants
.       Inflammatory Bowel Diseases
.       Interstitial Cystitis
.       Lung Injury
.       Metals Toxicology
.       Mitochondrial Disease
.       Musculoskeletal Disorders
.       Myotonic Dystrophy
.       Nanomaterials for Bone Regeneration
.       Nutrition Optimization
.       Pancreatitis
.       Pathogen-Inactivated Blood Products
.       Polycystic Kidney Disease
.       Post-Traumatic Osteoarthritis
.       Pressure Ulcers
.       Pulmonary Fibrosis
.       Resilience Training
.       Respiratory Health
.       Rett Syndrome
.       Rheumatoid Arthritis
.       Scleroderma
.       Sleep Disorders
.       Spinal Muscular Atrophy
.       Tinnitus
.       Tissue Regeneration
.       Tuberculosis
.       Vascular Malformations
.       Women's Heart Disease
 

The following mechanisms are planned for release:
       
http://cdmrp.army.mil/pubs/press/2019/19prmrppreann

Clinical Trial Award
.       Assistant Professor level or above (or equivalent)
.       Preproposal submission is required; application submission is by invitation only.
.       Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic         area(s) of interest.
.       Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.
.       Investigational New Drug or Investigational Device Exemption applications, if needed, should be approved by the Food and Drug Administration before      the PRMRP application submission deadline.
.       Funding limit not defined; requested funding must be appropriate for the scope of work proposed
.       Maximum period of performance is 4 years

Discovery Award
.       Postdoctoral fellow or clinical fellow (or equivalent) and above
.       Supports the exploration of a highly innovative new concept or untested theory.
.       Not intended to support the logical progression of an already established line of questioning.
.       Clinical trials will not be funded.
.       Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organization(s).
.       Maximum of $200,000 for direct costs (plus indirect costs)
.       Maximum period of performance is 2 year

Focused Program Award
.       Full Professor level or above (or equivalent)
.       Preproposal submission is required; application submission is by invitation only.
.       Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal.
.       Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications.
.       Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.
.       Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects.
.       Maximum of $7.2 million for direct costs (plus indirect costs)
.       Maximum period of performance is 4 years

Investigator-Initiated Research Award
.       Assistant Professor level or above (or equivalent)
.       Preproposal submission is required; application submission is by invitation only.
.       Supports research that will make an original and important contribution to the field of research or patient care in the topic area(s) of interest.
.       Partnering PI Option available.
.       Clinical trials will not be funded.
.       Maximum of $1.2 million for direct costs (plus indirect costs)
.       Maximum of $1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option
.       Maximum period of performance is 3 years

Technology/ Therapeutic Development Award
.       Assistant Professor level or above (or equivalent)
.       Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life.
.       Product-oriented (e.g., device, drug, clinical guidelines).  The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or       biologics) or device, or a knowledge-based product.
.       Clinical trials will not be funded.
.       Preproposal submission is required; application submission is by invitation only.
.       Maximum of $3.0 million for direct costs (plus indirect costs)
.       Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government's single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under "Email Subscriptions" on the eBRAP homepage at https://eBRAP.org.  For more information about the PRMRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:
CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil
Book mark the CDMRP website:
cdmrp.army.mil

Follow CDMRP on Twitter at:
twitter.com/CDMRP

View CDMRP research results on YouTube:
www.youtube.com/user/CDMRP

Like us on FaceBook:
www.facebook.com/TheCDMRP